1
Investing in Emerging Market Equities During the COVID-19 Crisis
Justin Kuepper
|
Let’s take a look at how COVID-19 has impacted emerging markets and how...
Welcome to MutualFunds.com
Please help us personalize your experience and select the one that best describes you.
Your personalized experience is almost ready.
Thank you!
Check your email and confirm your subscription to complete your personalized experience.
Thank you for your submission
We hope you enjoy your experience
Fixed income news, reports, video and more.
Municipal bonds news, reports, video and more.
Practice management news, reports, video and more.
Portfolio management news, reports, video and more.
Retirement news, reports, video and more.
Learn from industry thought leaders and expert market participants.
Find the latest content and information here about the 2019 Charles Schwab Impact Conference.
18 Most Popular Mutual Fund Categories
View All Categories
15 Most Popular Fund Company Quick Screens
View All Fund Company Quick Screens
Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.
Content focused on helping financial advisors build successful client relationships and grow their business.
Content geared towards helping financial advisors build better client portfolios.
Get insights on the industry trends and investment news from leading fund managers and experts.
Gilead shares are pulling back significantly on today’s news. The only argument that Gilead could have is that today’s announcement limits patients’ options for treatment.
This is a very important event for biotech investors to be aware of since there could be similar moves in the near future, which can impact other biotech companies. If Express Scripts is saving by choosing the cheaper option, its peers including CVS Health (CVS), Aetna (AET) and UnitedHealth (UNH) could follow suit.
It is hard to say if investors should head for the exits on today’s biotech-related headlines. Considering the sector has had consecutive 50% gains, some profit-taking is likely in the cards.
| Symbol | Mutual Fund | Stake |
|---|---|---|
| Liquid error: internal | Vanguard Total Stock Mkt Idx | 1.37% |
| Liquid error: internal | Fidelity® Contrafund® | 1.34% |
| Liquid error: internal | Vanguard 500 Index | 1.28% |
Shares of GILD are up 28% YTD.
Receive email updates about best performers, news, CE accredited webcasts and more.
Justin Kuepper
|
Let’s take a look at how COVID-19 has impacted emerging markets and how...
Kristan Wojnar, RCC™
|
This week we are highlighting the themes of virtual tools, learning from your...
News
Iuri Struta
|
Mid-cap stocks and investment-grade bonds were favored by investors these past two weeks.
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
Gilead shares are pulling back significantly on today’s news. The only argument that Gilead could have is that today’s announcement limits patients’ options for treatment.
This is a very important event for biotech investors to be aware of since there could be similar moves in the near future, which can impact other biotech companies. If Express Scripts is saving by choosing the cheaper option, its peers including CVS Health (CVS), Aetna (AET) and UnitedHealth (UNH) could follow suit.
It is hard to say if investors should head for the exits on today’s biotech-related headlines. Considering the sector has had consecutive 50% gains, some profit-taking is likely in the cards.
| Symbol | Mutual Fund | Stake |
|---|---|---|
| Liquid error: internal | Vanguard Total Stock Mkt Idx | 1.37% |
| Liquid error: internal | Fidelity® Contrafund® | 1.34% |
| Liquid error: internal | Vanguard 500 Index | 1.28% |
Shares of GILD are up 28% YTD.
Receive email updates about best performers, news, CE accredited webcasts and more.
Justin Kuepper
|
Let’s take a look at how COVID-19 has impacted emerging markets and how...
Kristan Wojnar, RCC™
|
This week we are highlighting the themes of virtual tools, learning from your...
News
Iuri Struta
|
Mid-cap stocks and investment-grade bonds were favored by investors these past two weeks.
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Download our free report
Find out why $30 trillon is invested in mutual funds.
Mutual Fund Education
Justin Kuepper
|
Let's take a closer look at how ESG investments have outperformed during the...
Mutual Fund Education
Daniel Cross
|
While CITs and mutual funds share many similarities, there are some key differences...
Mutual Fund Education
Sam Bourgi
|
The phrase ‘bear market’ has been thrown around a lot lately, but it...
TAXATION
For mutual fund investors, taxes are inevitable. Even if you’re a long-term buy...
MUTUAL FUND EDUCATION
Many investors assume that changes in a mutual fund’s net asset value (NAV)...
MUTUAL FUND EDUCATION
For investors looking to add mutual funds to their portfolio, they need to...
Receive email updates about best performers, news, CE accredited webcasts and more.
Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.